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Background
Although much research has investigated treatment dis-
continuation and virologic failure (VF) to first-line ART
regimens, less is known about second-line responses.
Methods
We included patients at the Royal Free Hospital, London,
who were ARV-naïve when starting their first ART regimen
(>=3 ARVs) and who: (i) experienced VF to their first ART
regimen (at least one viral load >400 cps/ml after >4
months continuous exposure to an ARV); (ii) started sec-
ond-line ART (defined by the first date on which at least
one PI/NNRTI and/or at least two new NRTIs were started
after VF to the first-line regimen occurred) with a latest
viral load >400 cps/ml. Time to VF (the first of two con-
secutive viral loads >400 cps/ml more than 4 months after
starting their second-line regimen; ARV changes/discon-
tinuations ignored) was calculated using survival analysis.
Summary of results
166 patients started second-line ART with a median (IQR)
CD4 count and viral load of 256 (120–358) cells/mm3
and 4.3 (3.3–5.0) log cps/ml. Twenty-five (15%), 48
(29%) and 93 (56%) patients second-line regimen
included one, two and >=3 antiretrovirals they had not
previously received. The median (95% CI) time to discon-
tinuing at least one ARV was 15 (12–19) months, and 24
(17–41) months for discontinuing a PI/NNRTI. Few fac-
tors were associated with time to first discontinuation of
any ARV: compared to those starting a second-line regi-
men containing one new ARV, the adjusted hazard ratios
were 0.56 (0.33–0.95) and 0.50 (0.30,0.83; p = 0.001) for
those receiving two and >=3 new ARVs. Each additional
year in time from first VF to start of second-line regimen
was associated with a 19% reduced hazard of discontinu-
ing (0.66–0.99; p = 0.04). 29% (22–36%) and 44% (36–
52%) experienced VF by 12 and 36 months after starting
second-line cART. This compares to 14% and 27%
amongst those on first-line cART. The only factors associ-
ated with VF in multivariable analysis were the inclusion
of fewer new ARVs in the second-line regimen (compared
to one: HR = 0.1; 0.13–0.75 for two, and 0.26; 0.12–0.60;
p = 0.01 for >=3 new ARVs), lower CD4 count (HR = 0.73
per 100 cells/mm3; 0.59–0.96; p = 0.03), and higher viral
load at the start of the second-line regimen (HR = 2.56 per
1 log cps/ml; 1.33–4.94; p = 0.005).
Conclusion
The median time to making at least one ARV switch on a
second-line regimen was comparable to that seen on first-
line regimens. Although VF appeared more common on
second-line than on first-line regimens, perhaps because
this is a group who are more predisposed to VF, response
rates were still excellent.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):O37 doi:10.1186/1758-2652-11-S1-O37
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/O37
© 2008 Smith et al; licensee BioMed Central Ltd. 
